English
Polski
Español
українська
Antiviral drugs in HIV treatment and neuropathic pain
How often is neuropathic pain caused by antiviral drugs in HIV treatment?
2018-08-23
How often is neuropathic pain caused by antiviral drugs in HIV treatment?
Is there a risk of H7N9 influenza spreading from China to other countries?
Should members of the hospital personnel who do not have direct contact with patients and who are carriers of a multidrug-resistant strain, such as methicillin-resistant Staphylococcus aureus, continue to work as normal?
Is a confirmed carrier status of methicillin-resistant Staphylococcus aureus (MRSA) or other drug-resistant bacteria in a health-care worker an indication for treatment? Should the worker refrain from having contact with patients?
Should the health-care personnel treating a patient infected with a multidrug-resistant strain undergo carrier screening? If yes, when should the tests be performed: on a regular basis in all staff or only in case of exposure?
Is it advisable to perform screening tests for certain drug-resistant pathogens in patients admitted to a hospital? If so, who should be tested? Should we perform such screening tests in patients with a history of documented drug-resistant bacterial strain infection?
What are the alternative treatments in patients with multidrug-resistant bacterial strain infections? Could such treatments (eg, phage therapy) offer a chance for cure in such patients?
Why has the emergence of New Delhi Metallo-beta-lactamase-1 (NDM-1) resistance caused concern of disease control authorities?
What are the key differences between microbial floras in the hospital and community settings?
Is the virulence of community-acquired and hospital drug-resistant bacterial strains (eg, methicillin-resistant Staphylococcus aureus) the same? Are drug-resistant strain infections limited to patients with risk factors or can they also affect healthy persons with no risk factors?
